keyword
MENU ▼
Read by QxMD icon Read
search

aromasin exemestane

keyword
https://www.readbyqxmd.com/read/26757739/aromatase-inhibitor-associated-arthralgia-the-importance-of-oncology-provider-patient-communication-about-side-effects-and-potential-management-through-physical-activity
#1
Kirsten A Nyrop, Leigh F Callahan, Christine Rini, Mary Altpeter, Betsy Hackney, Amy DePue, Anne Wilson, Arielle Schechter, Hyman B Muss
PURPOSE: Breast cancer survivors on aromatase inhibitors (AI) often experience side effects of joint pain, stiffness, or achiness (arthralgia). This study presents findings from a qualitative study of survivors on an AI regarding their knowledge of potential joint pain side effects and how both AI side effects and their management through moderate physical activity could be discussed during routine visits with their oncology provider. METHODS: Qualitative data from semi-structured interviews were content analyzed for emergent themes...
June 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/25653556/management-of-patients-with-hormone-receptor-positive-breast-cancer-with-visceral-disease-challenges-and-treatment-options
#2
REVIEW
Wael A Harb
Endocrine therapy is an important treatment option for women with hormone receptor-positive (HR+) advanced breast cancer (ABC), yet many tumors are either intrinsically resistant or develop resistance to these therapies. Treatment of patients with ABC presenting with visceral metastases, which is associated with a poor prognosis, is also problematic. There is an unmet need for effective treatments for this patient population. Although chemotherapy is commonly perceived to be more effective than endocrine therapy in managing visceral metastases, patients who are not in visceral crisis might benefit from endocrine therapy, avoiding chemotherapy-associated toxicities that might affect quality of life...
2015: Cancer Management and Research
https://www.readbyqxmd.com/read/23461041/mtor-inhibitors-in-the-treatment-of-breast-cancer
#3
REVIEW
Shaveta Vinayak, Robert W Carlson
The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly dysregulated in breast cancer. In preclinical studies, hyperactivation of the PI3K pathway has been linked to resistance to both endocrine therapy and trastuzumab (Herceptin). Rapalogs, agents that primarily inhibit mTOR-raptor complex 1, have been studied in combination with endocrine therapy to overcome endocrine resistance.Trials of combination endocrine therapy and rapalogs in metastatic hormone receptor-positive breast cancer have demonstrated variable results...
January 2013: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/20193775/efficacy-of-exemestane-a-new-generation-of-aromatase-inhibitor-on-sex-differentiation-in-a-gonochoristic-fish
#4
COMPARATIVE STUDY
Sabina Ruksana, Narayan P Pandit, Masaru Nakamura
We report the first use of exemestane (EM), a steroidal aromatase inhibitor (AI) commercially known as aromasin, in studies of sex differentiation in fish. The effectiveness of EM was examined in two different age groups of the gonochoristic fish, Nile tilapia (Oreochromis niloticus). Untreated control fish (all female) showed normal ovarian differentiation through 120 days after hatching (dah), whereas fish treated with EM at 1000 and 2000 microg/g of feed from 9 dah through 35 dah, the critical period for sex differentiation, exhibited complete testicular differentiation; all stages of spermatogenic germ cells were evident and well developed efferent ducts were present...
June 2010: Comparative Biochemistry and Physiology. Toxicology & Pharmacology: CBP
https://www.readbyqxmd.com/read/19441873/exemestane-a-review-of-its-use-in-postmenopausal-women-with-breast-cancer
#5
REVIEW
Emma D Deeks, Lesley J Scott
Exemestane (Aromasin) is an orally active steroidal irreversible inactivator of the aromatase enzyme indicated as an adjuvant treatment in postmenopausal women with estrogen receptor-positive early-stage breast cancer following 2-3 years of adjuvant treatment with tamoxifen, and for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen or other antiestrogen therapy. Exemestane is effective for the treatment of postmenopausal women with early-stage or advanced breast cancer...
2009: Drugs
https://www.readbyqxmd.com/read/18537915/evaluation-of-the-quality-and-accuracy-of-information-regarding-aromatase-inhibitors-available-on-the-internet
#6
Ceri Beaton, Rhodri J Codd, Phillip A Holland, Christopher A Gateley
The internet is commonly used by patients to access medical information, particularly where new treatments become available and are highlighted in the press. There is however, no regulation of the quality or accuracy of the information presented on web sites. The aim of this study was to evaluate the quality and accuracy of the information concerning the aromatase inhibitors (AIs). The three most popular search engines: Google, Yahoo, and MSN were utilized. The top ten "hits" for the generic and proprietary names of each AIs: anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) were evaluated using a 12-point score by a single assessor...
July 2008: Breast Journal
https://www.readbyqxmd.com/read/18423505/synthesis-of-exemestane-labelled-with-13-c
#7
Erminia Fontana, Alberto Pignatti, Danilo Giribone, Enrico Di Salle
The synthesis of exemestane Aromasin, an irreversible steroidal aromatase inhibitor, specifically labelled with (13)C is reported. The preparation of [(13)C(3)]exemestane was achieved according to an eight-step procedure starting from the commercially available testosterone.
August 2008: Steroids
https://www.readbyqxmd.com/read/17623627/aromatase-inhibitors-and-musculoskeletal-pain-in-patients-with-breast-cancer
#8
REVIEW
Loren Winters, Karleen Habin, Joan Gallagher
Aromatase inhibitors are recommended for use by postmenopausal women who have estrogen receptor-positive early-stage breast cancer. They reduce local and distant recurrence more effectively than tamoxifen. Anastrozole (Arimidex, AstraZeneca Pharmaceuticals LP), letrozole (Femara, Novartis Pharmaceuticals Corporation), and exemestane (Aromasin, Pfizer Inc.) inhibit aromatase activity, thus significantly decreasing estrogen production in tissues such as liver, muscle, and fat. Very low levels of estrogen may be one cause of musculoskeletal pain, a common side effect associated with the drugs...
June 2007: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/17261771/aromatase-inhibitors-structural-features-and-biochemical-characterization
#9
REVIEW
Yanyan Hong, Shiuan Chen
Aromatase is the enzyme synthesizing estrogens from androgens. In estrogen-dependent breast tumors, estrogens induce the expression of growth factors responsible for cancer cell proliferation. In situ estrogen synthesis by aromatase "is thought to play a key role in the promotion of breast cancer growth. Aromatase inhibitors (AIs) provide new approaches for the prevention and treatment of breast cancer by inhibiting estrogen biosynthesis. Through reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical techniques, aromatase has been found to be expressed in many endocrine tissues and tumors originating from these tissues...
November 2006: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/16986348/aromatase-inhibitors-and-bone-loss
#10
REVIEW
Edith A Perez, Katherine Weilbaecher
The aromatase inhibitors (AIs) anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are significantly more effective than the selective estrogen-receptor modulator (SERM) tamoxifen in preventing recurrence in estrogen receptor-positive early breast cancer. Aromatase inhibitors are likely to replace SERMs as first-line adjuvant therapy for many patients. However, AIs are associated with significantly more osteoporotic fractures and greater bone mineral loss. As antiresorptive agents, oral and intravenous bisphosphonates such as alendronate (Fosamax), risedronate (Actonel), ibandronate (Boniva), pamidronate (Aredia), and zoledronic acid (Zometa) have efficacy in preventing postmenopausal osteoporosis, cancer treatment-related bone loss, or skeletal complications of metastatic disease...
August 2006: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/16157442/aromatase-inhibitors-and-cyclooxygenase-2-cox-2-inhibitors-in-endometriosis-new-questions-old-answers
#11
REVIEW
Andreas D Ebert, Julia Bartley, Matthias David
The medical treatment of endometriosis needs to be optimized. Therapeutic management strategies for endometriosis-associated pain or recurrent disease are primarily aimed at downregulating ovarian function or antagonizing the effect of estrogen in ectopic endometrial implants. In this context, basic research is providing important results for the development of new, specific treatment modalities. Aromatase overexpression has recently been detected in endometriotic tissue. Aromatase (p450arom) is responsible for converting C19 androgens into estrogen in several types of human tissue...
October 1, 2005: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/16088229/safety-considerations-of-adjuvant-therapy-in-early-breast-cancer-in-postmenopausal-women
#12
REVIEW
William J Gradishar
Because of its proven efficacy profile based on long-term data, tamoxifen has been the standard adjuvant endocrine therapy for hormone-sensitive early breast cancer for the past 30 years. However, there is well-established evidence that long-term use of tamoxifen is associated with serious side effects. As adjuvant endocrine therapy is generally administered for long periods of time, the safety and tolerability of agents used in this setting are of particular importance. Due to their superior efficacy over tamoxifen, newer agents, such as the third-generation aromatase inhibitors (AIs), are already established therapies for the treatment of advanced breast cancer...
2005: Oncology
https://www.readbyqxmd.com/read/15752382/a-predictive-model-for-exemestane-pharmacokinetics-pharmacodynamics-incorporating-the-effect-of-food-and-formulation
#13
RANDOMIZED CONTROLLED TRIAL
Marta Valle, Enrico Di Salle, Maria Gabriella Jannuzzo, Italo Poggesi, Maurizio Rocchetti, Riccardo Spinelli, Davide Verotta
AIMS: Exemestane (Aromasin) is an irreversible aromatase inactivator used for the treatment of postmenopausal women with advanced breast cancer. The objective of this study was to evaluate the effect of formulation comparing a sugar-coated tablet (SCT) with a suspension and food on the pharmacokinetics (PK) and pharmacodynamics (PD) with respect to plasma estrone sulphate (E1S) concentrations of exemestane, using a PK/PD approach. METHODS: This was an open, three-period, randomized, crossover study...
March 2005: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/15280184/reducing-breast-cancer-incidence-in-familial-breast-cancer-overlooking-the-present-panorama
#14
REVIEW
P Marchetti, C Z Di Rocco, E Ricevuto, R Bisegna, G Cianci, F Calista, T Sidoni, G Porzio, C Ficorella
Familial breast cancer, whether associated or not with particular other breast cancer features (male, early onset, bilateral breast cancer), determines a wide and variable risk of developing breast cancer in the 'unpatients' (unaffected individuals) of these families, particularly in those harboring a genetic predisposition. The antiestrogen tamoxifen has been proposed in different trials to prevent breast cancer in women at risk. The NSABP-P1 study demonstrated that tamoxifen drastically reduced (by approximately 50%) the incidence of breast cancer in women at risk selected according to the Gail score...
2004: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/15266091/tamoxifen-what-next
#15
REVIEW
William J Gradishar
Most patients with advanced breast cancer (ABC) ultimately die due to disease progression. Consequently, treatments for ABC are predominantly palliative in nature and, therefore, the tolerability profile of a given treatment is particularly relevant in these patients. While cytotoxic chemotherapy and endocrine therapy exhibit efficacy in hormone-sensitive, advanced disease, it is endocrine therapy that combines efficacy with minimal acute toxicity. Tamoxifen has been the chosen endocrine therapy for postmenopausal, hormone-sensitive, ABC for over 20 years...
2004: Oncologist
https://www.readbyqxmd.com/read/15217586/-adjuvant-treatment-of-breast-cancer-by-concomitant-hormonotherapy-and-radiotherapy-state-of-the-art
#16
REVIEW
D Azria, C Lemanski, A Zouhair, M Gutowski, Y Belkacémi, J B Dubois, G Romieu, M Ozsahin
Combining radiation and hormone therapy has become common clinical practice in recent years for locally advanced prostate cancer. The use of such concomitant therapy in the treatment of breast disease has been very infrequently reported in the literature, but such an application seems justified given the common hormonal dependence of breast cancer and the potential synergetic effect of these two treatment modalities. As adjuvant therapy, tamoxifen is the key drug in the hormonal treatment arsenal, providing a significant improvement in both local control and global survival rates...
June 2004: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/14671195/pharmacokinetics-and-dose-finding-of-a-potent-aromatase-inhibitor-aromasin-exemestane-in-young-males
#17
RANDOMIZED CONTROLLED TRIAL
Nelly Mauras, John Lima, Deval Patel, Annie Rini, Enrico di Salle, Ambrose Kwok, Barbara Lippe
Suppression of estrogen, via estrogen receptor or aromatase blockade, is being investigated in the treatment of different conditions. Exemestane (Aromasin) is a potent and selective irreversible aromatase inhibitor. To characterize its suppression of estrogen and its pharmacokinetic (PK) properties in males, healthy eugonadal subjects (14-26 yr of age) were recruited. In a cross-over study, 12 were randomly assigned to 25 and 50 mg exemestane daily, orally, for 10 d with a 14-d washout period. Blood was withdrawn before and 24 h after the last dose of each treatment period...
December 2003: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/14501171/-pharmacological-and-clinical-profile-of-exemestane-aromasin-a-novel-irreversible-aromatase-inhibitor
#18
REVIEW
Makoto Tahara, Shunji Nomura, Munehiro Hashimoto
Aromatase is the rate-limiting enzyme playing a role at the final step of estrogen biosynthesis, which is attracting attention as the target enzyme of hormone therapy of postmenopausal breast cancer. Exemestane (Aromasin) is a novel steroidal irreversible aromatase inhibitor that was approved in Japan as a therapeutic drug for postmenopausal breast cancer. Exemestane selectively inhibits aromatase activity in vitro, in a time-dependent and irreversible manner, suggesting the mechanism of action that exemestane covalently binds to aromatase as a pseudo-substrate and inactivates the enzyme...
October 2003: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/12902874/emerging-role-of-aromatase-inhibitors-in-the-adjuvant-setting
#19
REVIEW
Paul E Goss
Aromatase inhibitors (AIs) have been approved as second-line treatment for estrogen receptor-positive (ER+) metastatic breast cancer after first-line treatment with the selective estrogen receptor modulator (SERM) tamoxifen. Anastrozole and letrozole have also recently been widely approved as first-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer. The three third-generation selective oral AIs approved for use in the United States include two nonsteroidal agents, anastrozole (Arimidex) and letrozole (Femara), and the irreversible steroidal inhibitor exemestane (Aromasin)...
August 2003: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/12800793/long-term-toxicities-of-selective-estrogen-receptor-modulators-and-antiaromatase-agents
#20
REVIEW
Joanne E Mortimer, Janice H Urban
Published literature indicates that the selective estrogen-receptor modulators (SERMs) tamoxifen and raloxifene (Evista) have favorable effects on bone density, lipid profiles, and the incidence of second breast cancers, and unfavorable effects on the incidence of venous thrombosis and hot flushes. Tamoxifen increases the risk of endometrial cancer, but raloxifene does not. The effects of SERMs on sexual function and cognition are unclear. Because the selective antiaromatase agents are relatively new, the long-term effects of these agents on normal tissues are less well established...
May 2003: Oncology (Williston Park, NY)
keyword
keyword
167624
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"